GLP-1 medication

Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic face heightened health risks during the current heat wave. The drugs can contribute to dehydration, and patients may not feel thirsty or may experience nausea and vomiting, making it harder to stay hydrated. Medical experts are advising users to drink water regularly, avoid excessive heat, and seek medical attention if they develop dizziness or other symptoms of dehydration.

Psychologist Ana Beatriz Barbosa discusses whether slimming pens — injectable weight-loss medications such as GLP-1 treatments — can influence mood and mental health. The conversation examines possible psychological effects of rapid weight loss, appetite suppression and changes in the brain's reward system, a growing concern as these drugs spread widely.

Eating disorder treatment providers and people in recovery in Philadelphia are describing how the rise of GLP-1 weight loss drugs such as Ozempic is reshaping their work and recovery. Clinicians say the widespread embrace of injectable weight loss medications has complicated treatment, reintroducing diet-focused messaging that patients in recovery find triggering, while navigating a cultural shift toward medicalized weight loss.

The World Health Organization has released new guidelines on managing obesity in children, addressing the role of GLP-1 weight-loss drugs and surgery in treatment. The recommendations come as childhood obesity rates climb worldwide and new medications reshape the debate over how best to treat the condition in young patients.

AgFunderNews explores whether the rise of GLP-1 weight-loss drugs could finally give crop nutrient density a market price. As appetite-suppressing medications reshape how much food people consume, the argument goes that farmers and food companies may need to compete on the nutritional quality of every calorie, rather than volume alone, potentially reshaping agricultural economics.

A new study is examining whether GLP-1 weight-loss and diabetes medications, such as Ozempic and Wegovy, may be linked to nail problems in some patients. Researchers are looking at reported changes to nail health among people taking the widely used drugs. The findings could add to the growing list of side effects being studied as use of GLP-1 medications expands worldwide.

A new study reports that young people taking GLP-1 weight-loss and diabetes drugs show nutritional deficiencies, raising questions about whether appetite suppression on these medications is leading to inadequate intake of key nutrients. The findings add to ongoing scrutiny of the drugs' side effects and are likely to fuel debate over dietary guidance for the growing number of young patients using them.

The Department of Veterans Affairs and Department of Defense have issued a new obesity guideline that strongly recommends GLP-1 medications semaglutide and tirzepatide for weight management in veterans and service members. The recommendation is drawing attention because it signals growing official acceptance of newer weight-loss drugs and could influence care for millions of patients across the military health system.

New guidance from the Mayo Clinic addresses how patients can maintain weight loss after discontinuing GLP-1 medications such as Ozempic and Wegovy. The advice comes as many users regain weight once treatment ends, prompting debate among clinicians about long-term diet, exercise and follow-up strategies.

The World Health Organization has endorsed lifestyle changes as the primary approach to tackling childhood obesity, positioning them ahead of GLP-1 weight-loss drugs such as those making headlines worldwide. According to Reuters, the guidance signals caution about relying on medication for children, favoring diet, exercise and behavioral support as the first line of response to rising obesity rates.

Giant, the US grocery retailer, is broadening its nutrition and pharmacy services for customers taking GLP-1 weight-loss and diabetes medications. The expansion is aimed at helping shoppers manage diet and medication needs alongside their prescriptions. Retail industry press flagged the move as grocers increasingly build services around the fast-growing GLP-1 drug market.

Dutch supplement maker XXL Nutrition has developed a Daily Support Protein aimed at people using GLP-1 weight-loss medications such as Ozempic and Wegovy. The product is designed to help users maintain adequate protein intake while these appetite-suppressing drugs reduce how much they eat. It signals supplement makers moving to serve the fast-growing population on GLP-1 therapy.

Apparel retailers are rethinking their sizing and fit strategies as growing numbers of customers lose significant weight on GLP-1 medications such as Ozempic and Wegovy. The industry is working to find new fits for thinner consumers, adjusting clothing lines, tailoring services and size ranges to serve shoppers whose body shapes are changing rapidly.

Danone has developed a new drink targeting consumers taking weight loss medications such as GLP-1 drugs, according to a report carried by Polish Radio. The product is aimed at people whose reduced appetite on these treatments creates demand for nutrient-dense foods and drinks. The move reflects how major food companies are adapting product lines to the rapid rise of anti-obesity medication use worldwide.

A new study suggests children taking GLP-1 weight-loss and diabetes drugs may be at risk of nutritional deficiencies. The findings raise concerns about how appetite suppression and reduced food intake from medications like Ozempic and Wegovy could affect growing bodies, adding to the ongoing debate over the safety of prescribing these drugs to young patients.

Giant Co., the US grocery retailer, is broadening its well-being services tailored to customers using GLP-1 weight-loss medications. The expanded offerings are aimed at supporting shoppers on drugs like Ozempic and Wegovy with nutrition guidance and related in-store and pharmacy resources. The move reflects how grocers are racing to serve the fast-growing population of Americans taking GLP-1 treatments.

A new GLP-1 drug is under scrutiny as commentators ask whether it is a genuine medical advance or an overhyped product with unproven safety. GLP-1 medications, already widely used for diabetes and weight loss, have surged in popularity, and each new entrant prompts questions about side effects, long-term risks and who should take them. Coverage so far frames the drug as part of an ongoing debate rather than reporting confirmed safety problems.

Weight-loss medications such as GLP-1 drugs are changing how gyms operate, as more members combine medication with training. The report examines how fitness businesses are adapting their programmes and services to a growing clientele using these drugs, and what the shift means for the industry's traditional focus on exercise alone as the path to losing weight.

Users of Ozempic and similar GLP-1 weight-loss and diabetes drugs are reporting brittle or damaged nails, in addition to previously reported hair loss. The side effects are believed to be linked to rapid weight loss and reduced nutrient intake rather than the drug itself. Gizmodo's report is drawing attention to the growing list of cosmetic complaints from patients, as prescriptions for GLP-1 medications continue to surge worldwide.

A new report warns that children taking GLP-1 medications for weight management may face nutrition risks, as the appetite-suppressing drugs can make it harder for growing bodies to get enough protein, vitamins and minerals. Health commentators stress that kids on these treatments need careful dietary monitoring and professional guidance to avoid deficiencies during development.

Commentators are speculating ahead of the 2026 Nobel Prize in Medicine, arguing the field has two leading contenders. One lane centers on GLP-1 weight-loss drugs such as Ozempic, which have transformed obesity treatment and become a major cultural and scientific phenomenon. The other leading area is unnamed in current discussion, but observers say both fields have strong cases for recognition when the prize is announced.

The New York Times reports that GLP-1 weight loss medications are changing restaurant economics, as diners on the drugs order less food and restaurants must adapt to smaller appetites. The piece examines how chains and independent eateries are responding to customers who eat less per visit, a shift with potential implications for portions, menu design and revenue.

The American Academy of Optometry's 2026 meeting is spotlighting the ocular effects of GLP-1 receptor agonists, the class of drugs that includes semaglutide and tirzepatide. Clinicians are discussing how these widely used diabetes and weight-loss medications may affect the eye, from reported changes in diabetic retinopathy to dry-eye symptoms, and what optometrists should monitor in patients taking them.

Doctors are warning that using GLP-1 weight-loss and diabetes medicines without consulting a medical expert is dangerous. The caution comes as these drugs grow in popularity, with concerns that people may self-medicate without proper dosage guidance or monitoring for side effects. Physicians stress that such medicines should only be taken under professional supervision.

New reporting indicates that nearly one in six pediatric patients taking GLP-1 medications for weight management show signs of nutritional deficiency. The finding raises concerns among clinicians about monitoring children's diets and micronutrient intake while on these increasingly prescribed obesity drugs. Health experts are urging careful dietary assessment and follow-up care for young patients treated with GLP-1 therapies.

The New York Times reports that the growing popularity of weight loss drugs like Ozempic is creating a new challenge for the restaurant industry, as customers on these medications are ordering and eating less food. The trend is prompting restaurants and food businesses to rethink portion sizes, menus, and sales expectations as appetite suppression reshapes dining habits.

Nextida GC, a collagen peptide ingredient, is being reported to support the body's natural production of GLP-1, the gut hormone targeted by popular weight-loss and diabetes drugs. The announcement, covered by supplement industry press, positions the ingredient for the booming market in natural alternatives to GLP-1 medications. Details of the underlying research and its strength have not been provided in initial coverage.

Health apps that have been profiting from selling copycat versions of weight-loss drugs may soon face regulatory or legal limits, according to a Polish Radio report. The item suggests the current business model — telehealth platforms dispensing compounded or imitation GLP-1 medications — is on borrowed time, though no specific companies, regulators or dates are named.

Amazon's One Medical has launched a new program offering GLP-1 weight-loss medications to patients. The move puts Amazon further into healthcare, giving users access to popular appetite-suppressant drugs through its medical service. The expansion comes amid surging demand for GLP-1 treatments and growing competition among retailers and telehealth providers to offer them.

Startup accelerator Plug & Play is turning its attention to companion nutrition for people taking GLP-1 weight-loss and diabetes drugs, framing it as the next frontier for the microbiome sector. The idea is that patients on medications like Ozempic, who eat less, may need tailored probiotic and nutrient support to protect gut health and muscle mass while losing weight.

Some patients taking GLP-1 weight-loss drugs such as Ozempic and Wegovy are experimenting with microdosing, using lower doses than prescribed, often to cut costs or reduce side effects. An obesity medicine doctor is explaining what the practice involves and urging caution, since evidence for smaller-than-approved doses is limited and self-adjusting medication without medical supervision carries risks.

New research indicates that close to one in six children taking GLP-1 weight-loss and diabetes medications develop nutritional deficiencies. The findings raise questions about monitoring and dietary support for young patients on these increasingly prescribed drugs, as clinicians weigh the benefits of treatment against potential long-term nutritional risks in children.